CA2657521A1 - Toxines clostridiennes modifiees a capacite de translocation amelioree et a activite modifiee de ciblage des cellules qui ne sont pas cibles des toxines clostridiennes - Google Patents

Toxines clostridiennes modifiees a capacite de translocation amelioree et a activite modifiee de ciblage des cellules qui ne sont pas cibles des toxines clostridiennes Download PDF

Info

Publication number: CA2657521A1
Authority: CA; Canada
Prior art keywords: amino acids; bont; seq; clostridial toxin; amino acid
Prior art date: 2006-07-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002657521A

Other languages

English (en)

Inventor

Lance E. Steward

Joseph Francis

Ester Fernandez-Salas

Marcella A. Gilmore

Shengwen Li

Kei Roger Aoki

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Allergan Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-07-11

Filing date

2007-07-11

Publication date

2008-01-17

2007-07-11 Application filed by Individual filed Critical Individual

2008-01-17 Publication of CA2657521A1 publication Critical patent/CA2657521A1/fr

Status Abandoned legal-status Critical Current

Links

231100001102 clostridial toxin Toxicity 0.000 title claims abstract description 639
230000005945 translocation Effects 0.000 title claims abstract description 190
230000008685 targeting Effects 0.000 title claims description 66
230000000694 effects Effects 0.000 title description 15
238000000034 method Methods 0.000 claims abstract description 80
230000002255 enzymatic effect Effects 0.000 claims abstract description 74
108091033319 polynucleotide Proteins 0.000 claims abstract description 13
102000040430 polynucleotide Human genes 0.000 claims abstract description 13
239000002157 polynucleotide Substances 0.000 claims abstract description 13
108090000765 processed proteins & peptides Proteins 0.000 claims description 560
102000004196 processed proteins & peptides Human genes 0.000 claims description 359
229920001184 polypeptide Polymers 0.000 claims description 358
230000000799 fusogenic effect Effects 0.000 claims description 191
241000700605 Viruses Species 0.000 claims description 118
108091005804 Peptidases Proteins 0.000 claims description 42
239000004365 Protease Substances 0.000 claims description 41
230000027455 binding Effects 0.000 claims description 35
230000008569 process Effects 0.000 claims description 33
102000005962 receptors Human genes 0.000 claims description 29
108020003175 receptors Proteins 0.000 claims description 29
231100000566 intoxication Toxicity 0.000 claims description 28
230000035987 intoxication Effects 0.000 claims description 28
230000007017 scission Effects 0.000 claims description 26
238000003776 cleavage reaction Methods 0.000 claims description 25
102100024304 Protachykinin-1 Human genes 0.000 claims description 6
230000004048 modification Effects 0.000 claims description 6
238000012986 modification Methods 0.000 claims description 6
101800000414 Corticotropin Proteins 0.000 claims description 3
108010093008 Kinins Proteins 0.000 claims description 3
108010008364 Melanocortins Proteins 0.000 claims description 3
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 3
229960000258 corticotropin Drugs 0.000 claims description 3
108060008037 tachykinin Proteins 0.000 claims description 3
102000007345 Chromogranins Human genes 0.000 claims description 2
108010007718 Chromogranins Proteins 0.000 claims description 2
101710183734 Peptide YY-like Proteins 0.000 claims description 2
102000003141 Tachykinin Human genes 0.000 claims description 2
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 10
101800001982 Cholecystokinin Proteins 0.000 claims 3
102400001370 Galanin Human genes 0.000 claims 3
101800002068 Galanin Proteins 0.000 claims 3
239000000637 Melanocyte-Stimulating Hormone Substances 0.000 claims 3
SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 claims 3
241001367053 Autographa gamma Species 0.000 claims 2
102400000967 Bradykinin Human genes 0.000 claims 2
101800004538 Bradykinin Proteins 0.000 claims 2
YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 claims 2
102400000741 Corticotropin-like intermediary peptide Human genes 0.000 claims 2
101800001708 Corticotropin-like intermediary peptide Proteins 0.000 claims 2
102400001223 Galanin message-associated peptide Human genes 0.000 claims 2
101800000863 Galanin message-associated peptide Proteins 0.000 claims 2
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims 2
101800000923 Neuropeptide K Proteins 0.000 claims 2
102400001169 Pancreatic icosapeptide Human genes 0.000 claims 2
102100029909 Peptide YY Human genes 0.000 claims 2
108010088847 Peptide YY Proteins 0.000 claims 2
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims 2
239000002865 melanocortin Substances 0.000 claims 2
108010046794 pancreatic eicosapeptide Proteins 0.000 claims 2
IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 claims 2
NYBLUYYRUFKGTB-XJCFQSCISA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]acetyl]amino]hexanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]-n-[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl- Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](N)[C@@H](C)O)C1=CC=CC=C1 NYBLUYYRUFKGTB-XJCFQSCISA-N 0.000 claims 1
IVCOLVXXCVGZJW-CCPSMLFMSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxo-3-(4-sulfooxyphenyl)propan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccc(OS(O)(=O)=O)cc1)C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O IVCOLVXXCVGZJW-CCPSMLFMSA-N 0.000 claims 1
PLSDWRYNZIVQKX-BGKYVOMCSA-N (3S)-3-amino-4-[[(2S)-1-[[2-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S,3R)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(1S)-1-carboxy-3-methylsulfanylpropyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CC4=CNC=N4)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)N PLSDWRYNZIVQKX-BGKYVOMCSA-N 0.000 claims 1
108010083813 BAM22 peptide Proteins 0.000 claims 1
102100025841 Cholecystokinin Human genes 0.000 claims 1
102400000885 Cholecystokinin-12 Human genes 0.000 claims 1
101800001115 Cholecystokinin-12 Proteins 0.000 claims 1
102400000883 Cholecystokinin-33 Human genes 0.000 claims 1
101800001100 Cholecystokinin-33 Proteins 0.000 claims 1
102400000880 Cholecystokinin-39 Human genes 0.000 claims 1
101800001099 Cholecystokinin-39 Proteins 0.000 claims 1
102400000879 Cholecystokinin-58 Human genes 0.000 claims 1
101800004067 Cholecystokinin-58 Proteins 0.000 claims 1
102400000888 Cholecystokinin-8 Human genes 0.000 claims 1
101800005151 Cholecystokinin-8 Proteins 0.000 claims 1
102000010792 Chromogranin A Human genes 0.000 claims 1
108010038447 Chromogranin A Proteins 0.000 claims 1
102000010791 Chromogranin B Human genes 0.000 claims 1
108010038439 Chromogranin B Proteins 0.000 claims 1
108010022152 Corticotropin-Releasing Hormone Proteins 0.000 claims 1
239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims 1
102000012289 Corticotropin-Releasing Hormone Human genes 0.000 claims 1
101710134516 Des-Arg9-bradykinin Proteins 0.000 claims 1
108010065372 Dynorphins Proteins 0.000 claims 1
108010049140 Endorphins Proteins 0.000 claims 1
102000009025 Endorphins Human genes 0.000 claims 1
108010092674 Enkephalins Proteins 0.000 claims 1
101800000637 Hemokinin Proteins 0.000 claims 1
101000603877 Homo sapiens Nuclear receptor subfamily 1 group I member 2 Proteins 0.000 claims 1
101000613565 Homo sapiens PRKC apoptosis WT1 regulator protein Proteins 0.000 claims 1
101001135199 Homo sapiens Partitioning defective 3 homolog Proteins 0.000 claims 1
101001098529 Homo sapiens Proteinase-activated receptor 1 Proteins 0.000 claims 1
101001098560 Homo sapiens Proteinase-activated receptor 2 Proteins 0.000 claims 1
101001113471 Homo sapiens Proteinase-activated receptor 4 Proteins 0.000 claims 1
101000713170 Homo sapiens Solute carrier family 52, riboflavin transporter, member 1 Proteins 0.000 claims 1
101000713169 Homo sapiens Solute carrier family 52, riboflavin transporter, member 2 Proteins 0.000 claims 1
108010003195 Kallidin Proteins 0.000 claims 1
FYSKZKQBTVLYEQ-FSLKYBNLSA-N Kallidin Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 FYSKZKQBTVLYEQ-FSLKYBNLSA-N 0.000 claims 1
XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 claims 1
URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 claims 1
101710151321 Melanostatin Proteins 0.000 claims 1
102400000097 Neurokinin A Human genes 0.000 claims 1
101800000399 Neurokinin A Proteins 0.000 claims 1
HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 claims 1
102000046798 Neurokinin B Human genes 0.000 claims 1
NHXYSAFTNPANFK-HDMCBQFHSA-N Neurokinin B Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(O)=O)C1=CC=CC=C1 NHXYSAFTNPANFK-HDMCBQFHSA-N 0.000 claims 1
101800002813 Neurokinin-B Proteins 0.000 claims 1
102400000064 Neuropeptide Y Human genes 0.000 claims 1
102400001111 Nociceptin Human genes 0.000 claims 1
108090000622 Nociceptin Proteins 0.000 claims 1
102100024622 Proenkephalin-B Human genes 0.000 claims 1
102100037136 Proteinase-activated receptor 1 Human genes 0.000 claims 1
102100037132 Proteinase-activated receptor 2 Human genes 0.000 claims 1
102100023710 Proteinase-activated receptor 4 Human genes 0.000 claims 1
102000000705 Secretogranin II Human genes 0.000 claims 1
108010002533 Secretogranin II Proteins 0.000 claims 1
102000005157 Somatostatin Human genes 0.000 claims 1
108010056088 Somatostatin Proteins 0.000 claims 1
102100039365 Tachykinin-4 Human genes 0.000 claims 1
239000000627 Thyrotropin-Releasing Hormone Substances 0.000 claims 1
102400000336 Thyrotropin-releasing hormone Human genes 0.000 claims 1
101800004623 Thyrotropin-releasing hormone Proteins 0.000 claims 1
VCEHWDBVPZFHAG-POFDKVPJSA-N [des-Arg(9)]-bradykinin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CCC1 VCEHWDBVPZFHAG-POFDKVPJSA-N 0.000 claims 1
229940107137 cholecystokinin Drugs 0.000 claims 1
QFLBZJPOIZFFJQ-UHFFFAOYSA-N cholecystokinin 33 Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CCSC)C(=O)NC(CC(O)=O)C(=O)NC(CC=1C=CC=CC=1)C(N)=O)NC(=O)CNC(=O)C(CCSC)NC(=O)C(C=1C=CC(OS(O)(=O)=O)=CC=1)NC(=O)C(CC(O)=O)NC(=O)C(CCCNC(N)=N)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(C(C)CC)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(CO)NC(=O)C1N(CCC1)C(=O)C(CC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(N)=O)NC(=O)C(CCCCN)NC(=O)C(NC(=O)C(NC(=O)C(CO)NC(=O)C(CCSC)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(CO)NC(=O)C1N(CCC1)C(=O)C(C)NC(=O)C(N)CCCCN)C(C)CC)C(C)C)CC1=CNC=N1 QFLBZJPOIZFFJQ-UHFFFAOYSA-N 0.000 claims 1
229940041967 corticotropin-releasing hormone Drugs 0.000 claims 1
KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 claims 1
239000013604 expression vector Substances 0.000 claims 1
CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 claims 1
BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 claims 1
PULGYDLMFSFVBL-SMFNREODSA-N nociceptin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 PULGYDLMFSFVBL-SMFNREODSA-N 0.000 claims 1
URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 claims 1
XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 claims 1
229960002959 sincalide Drugs 0.000 claims 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 1
229960000553 somatostatin Drugs 0.000 claims 1
108010073085 tachykinin neuropeptide gamma Proteins 0.000 claims 1
229940034199 thyrotropin-releasing hormone Drugs 0.000 claims 1
WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 claims 1
235000001014 amino acid Nutrition 0.000 description 1798
150000001413 amino acids Chemical class 0.000 description 1624
125000003275 alpha amino acid group Chemical group 0.000 description 179
101710117542 Botulinum neurotoxin type A Proteins 0.000 description 148
101710117524 Botulinum neurotoxin type B Proteins 0.000 description 133
108030001722 Tentoxilysin Proteins 0.000 description 129
238000012217 deletion Methods 0.000 description 129
230000037430 deletion Effects 0.000 description 129
238000006467 substitution reaction Methods 0.000 description 129
101000985023 Clostridium botulinum C phage Botulinum neurotoxin type C Proteins 0.000 description 127
101710117515 Botulinum neurotoxin type E Proteins 0.000 description 126
101710117520 Botulinum neurotoxin type F Proteins 0.000 description 126
101000933563 Clostridium botulinum Botulinum neurotoxin type G Proteins 0.000 description 126
101000985020 Clostridium botulinum D phage Botulinum neurotoxin type D Proteins 0.000 description 125
102000001708 Protein Isoforms Human genes 0.000 description 111
108010029485 Protein Isoforms Proteins 0.000 description 111
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 102
230000006229 amino acid addition Effects 0.000 description 96
239000012634 fragment Substances 0.000 description 77
108030001720 Bontoxilysin Proteins 0.000 description 68
210000004027 cell Anatomy 0.000 description 50
239000003053 toxin Substances 0.000 description 37
231100000765 toxin Toxicity 0.000 description 37
108700012359 toxins Proteins 0.000 description 37
238000007792 addition Methods 0.000 description 33
102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 31
235000019419 proteases Nutrition 0.000 description 31
230000006870 function Effects 0.000 description 28
241000712461 unidentified influenza virus Species 0.000 description 27
210000000805 cytoplasm Anatomy 0.000 description 21
210000004379 membrane Anatomy 0.000 description 18
239000012528 membrane Substances 0.000 description 18
235000018102 proteins Nutrition 0.000 description 17
102000004169 proteins and genes Human genes 0.000 description 17
108090000623 proteins and genes Proteins 0.000 description 17
239000000758 substrate Substances 0.000 description 17
230000003957 neurotransmitter release Effects 0.000 description 14
230000006337 proteolytic cleavage Effects 0.000 description 14
230000003834 intracellular effect Effects 0.000 description 12
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 12
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 11
239000002581 neurotoxin Substances 0.000 description 10
231100000618 neurotoxin Toxicity 0.000 description 10
230000008520 organization Effects 0.000 description 10
230000007248 cellular mechanism Effects 0.000 description 9
230000033001 locomotion Effects 0.000 description 9
238000011282 treatment Methods 0.000 description 8
102000005917 R-SNARE Proteins Human genes 0.000 description 7
108010005730 R-SNARE Proteins Proteins 0.000 description 7
108010055044 Tetanus Toxin Proteins 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
208000035475 disorder Diseases 0.000 description 7
-1 galanins Proteins 0.000 description 7
125000006850 spacer group Chemical group 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
241001112695 Clostridiales Species 0.000 description 6
208000002193 Pain Diseases 0.000 description 6
102000000583 SNARE Proteins Human genes 0.000 description 6
108010041948 SNARE Proteins Proteins 0.000 description 6
102000039446 nucleic acids Human genes 0.000 description 6
108020004707 nucleic acids Proteins 0.000 description 6
150000007523 nucleic acids Chemical class 0.000 description 6
230000003612 virological effect Effects 0.000 description 6
241000710929 Alphavirus Species 0.000 description 5
241000035315 Avulavirus Species 0.000 description 5
241000035314 Henipavirus Species 0.000 description 5
241000282414 Homo sapiens Species 0.000 description 5
241000714192 Human spumaretrovirus Species 0.000 description 5
241000351643 Metapneumovirus Species 0.000 description 5
241000712045 Morbillivirus Species 0.000 description 5
241001113283 Respirovirus Species 0.000 description 5
241000711970 Vesiculovirus Species 0.000 description 5
238000013459 approach Methods 0.000 description 5
231100001103 botulinum neurotoxin Toxicity 0.000 description 5
239000008358 core component Substances 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
230000035772 mutation Effects 0.000 description 5
238000002864 sequence alignment Methods 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
206010033645 Pancreatitis Diseases 0.000 description 4
108010010469 Qa-SNARE Proteins Proteins 0.000 description 4
102000050389 Syntaxin Human genes 0.000 description 4
206010043376 Tetanus Diseases 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
230000008859 change Effects 0.000 description 4
239000002537 cosmetic Substances 0.000 description 4
239000003814 drug Substances 0.000 description 4
238000009510 drug design Methods 0.000 description 4
230000004927 fusion Effects 0.000 description 4
238000010353 genetic engineering Methods 0.000 description 4
230000003993 interaction Effects 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
239000000203 mixture Substances 0.000 description 4
238000002887 multiple sequence alignment Methods 0.000 description 4
210000002569 neuron Anatomy 0.000 description 4
238000002708 random mutagenesis Methods 0.000 description 4
230000002269 spontaneous effect Effects 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
238000012876 topography Methods 0.000 description 4
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 3
241001112696 Clostridia Species 0.000 description 3
108090001090 Lectins Proteins 0.000 description 3
102000004856 Lectins Human genes 0.000 description 3
101800003906 Substance P Proteins 0.000 description 3
241000711975 Vesicular stomatitis virus Species 0.000 description 3
230000008901 benefit Effects 0.000 description 3
229940053031 botulinum toxin Drugs 0.000 description 3
210000000170 cell membrane Anatomy 0.000 description 3
150000002270 gangliosides Chemical class 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
239000002523 lectin Substances 0.000 description 3
230000001537 neural effect Effects 0.000 description 3
239000002858 neurotransmitter agent Substances 0.000 description 3
210000002856 peripheral neuron Anatomy 0.000 description 3
238000011160 research Methods 0.000 description 3
230000001953 sensory effect Effects 0.000 description 3
229940118376 tetanus toxin Drugs 0.000 description 3
230000011215 vesicle docking Effects 0.000 description 3
241000711404 Avian avulavirus 1 Species 0.000 description 2
208000000094 Chronic Pain Diseases 0.000 description 2
241000186542 Clostridium baratii Species 0.000 description 2
241000193155 Clostridium botulinum Species 0.000 description 2
241000193171 Clostridium butyricum Species 0.000 description 2
241000193449 Clostridium tetani Species 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
241000710945 Eastern equine encephalitis virus Species 0.000 description 2
108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
206010019233 Headaches Diseases 0.000 description 2
208000004454 Hyperalgesia Diseases 0.000 description 2
108010039491 Ricin Proteins 0.000 description 2
241000710959 Venezuelan equine encephalitis virus Species 0.000 description 2
108010059722 Viral Fusion Proteins Proteins 0.000 description 2
239000000910 agglutinin Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
229940089093 botox Drugs 0.000 description 2
239000002775 capsule Substances 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
239000000306 component Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
210000000172 cytosol Anatomy 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000010586 diagram Methods 0.000 description 2
230000028023 exocytosis Effects 0.000 description 2
230000014509 gene expression Effects 0.000 description 2
231100000869 headache Toxicity 0.000 description 2
239000002596 immunotoxin Substances 0.000 description 2
210000003097 mucus Anatomy 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
230000024717 negative regulation of secretion Effects 0.000 description 2
210000005036 nerve Anatomy 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
239000011148 porous material Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000001273 protein sequence alignment Methods 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
239000003488 releasing hormone Substances 0.000 description 2
108010038196 saccharide-binding proteins Proteins 0.000 description 2
238000005070 sampling Methods 0.000 description 2
230000000946 synaptic effect Effects 0.000 description 2
108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
206010002153 Anal fissure Diseases 0.000 description 1
208000016583 Anus disease Diseases 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
208000003508 Botulism Diseases 0.000 description 1
102100021984 C-C motif chemokine 4-like Human genes 0.000 description 1
241000712083 Canine morbillivirus Species 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
101710089098 Cholecystokinins Proteins 0.000 description 1
241000193403 Clostridium Species 0.000 description 1
102400000739 Corticotropin Human genes 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
208000017701 Endocrine disease Diseases 0.000 description 1
108010059378 Endopeptidases Proteins 0.000 description 1
102000005593 Endopeptidases Human genes 0.000 description 1
208000000289 Esophageal Achalasia Diseases 0.000 description 1
206010063006 Facial spasm Diseases 0.000 description 1
208000009531 Fissure in Ano Diseases 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
208000004095 Hemifacial Spasm Diseases 0.000 description 1
241000893570 Hendra henipavirus Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000777471 Homo sapiens C-C motif chemokine 4 Proteins 0.000 description 1
101000896959 Homo sapiens C-C motif chemokine 4-like Proteins 0.000 description 1
208000035154 Hyperesthesia Diseases 0.000 description 1
208000008454 Hyperhidrosis Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
206010065390 Inflammatory pain Diseases 0.000 description 1
241000712431 Influenza A virus Species 0.000 description 1
241001500351 Influenzavirus A Species 0.000 description 1
102000002397 Kinins Human genes 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
STECJAGHUSJQJN-USLFZFAMSA-N LSM-4015 Chemical compound C1([C@@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-USLFZFAMSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
108010006035 Metalloproteases Proteins 0.000 description 1
102000005741 Metalloproteases Human genes 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000711408 Murine respirovirus Species 0.000 description 1
208000008238 Muscle Spasticity Diseases 0.000 description 1
208000029549 Muscle injury Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
102000005348 Neuraminidase Human genes 0.000 description 1
108010006232 Neuraminidase Proteins 0.000 description 1
208000007920 Neurogenic Inflammation Diseases 0.000 description 1
206010030136 Oesophageal achalasia Diseases 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
102000002020 Protease-activated receptors Human genes 0.000 description 1
108050009310 Protease-activated receptors Proteins 0.000 description 1
230000010799 Receptor Interactions Effects 0.000 description 1
241000710961 Semliki Forest virus Species 0.000 description 1
206010067672 Spasmodic dysphonia Diseases 0.000 description 1
208000004350 Strabismus Diseases 0.000 description 1
108010046722 Thrombospondin 1 Proteins 0.000 description 1
102100036034 Thrombospondin-1 Human genes 0.000 description 1
102000011923 Thyrotropin Human genes 0.000 description 1
108010061174 Thyrotropin Proteins 0.000 description 1
206010044074 Torticollis Diseases 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
108091006982 Zinc-dependent endopeptidases Proteins 0.000 description 1
102000036861 Zinc-dependent endopeptidases Human genes 0.000 description 1
108010079650 abobotulinumtoxinA Proteins 0.000 description 1
201000000621 achalasia Diseases 0.000 description 1
206010053552 allodynia Diseases 0.000 description 1
230000000721 bacterilogical effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
206010005159 blepharospasm Diseases 0.000 description 1
230000000744 blepharospasm Effects 0.000 description 1
238000010504 bond cleavage reaction Methods 0.000 description 1
206010006514 bruxism Diseases 0.000 description 1
206010008129 cerebral palsy Diseases 0.000 description 1
201000002866 cervical dystonia Diseases 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
229940098753 dysport Drugs 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
230000009144 enzymatic modification Effects 0.000 description 1
201000006517 essential tremor Diseases 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
230000037315 hyperhidrosis Effects 0.000 description 1
230000001660 hyperkinetic effect Effects 0.000 description 1
229960004716 idoxuridine Drugs 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
108010024001 incobotulinumtoxinA Proteins 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000749 insecticidal effect Effects 0.000 description 1
231100000567 intoxicating Toxicity 0.000 description 1
230000002673 intoxicating effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
239000003446 ligand Substances 0.000 description 1
201000003890 low compliance bladder Diseases 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000034217 membrane fusion Effects 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
230000002151 myoclonic effect Effects 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
230000001670 myorelaxant effect Effects 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
230000002981 neuropathic effect Effects 0.000 description 1
208000021722 neuropathic pain Diseases 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000001044 sensory neuron Anatomy 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000002689 soil Substances 0.000 description 1
201000002849 spasmodic dystonia Diseases 0.000 description 1
208000018198 spasticity Diseases 0.000 description 1
241000894007 species Species 0.000 description 1
210000002504 synaptic vesicle Anatomy 0.000 description 1
229960000874 thyrotropin Drugs 0.000 description 1
230000001748 thyrotropin Effects 0.000 description 1
230000007888 toxin activity Effects 0.000 description 1
230000024033 toxin binding Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
229940018272 xeomin Drugs 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
230000004572 zinc-binding Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA002657521A 2006-07-11 2007-07-11 Toxines clostridiennes modifiees a capacite de translocation amelioree et a activite modifiee de ciblage des cellules qui ne sont pas cibles des toxines clostridiennes Abandoned CA2657521A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US80705906P	2006-07-11	2006-07-11
US60/807,059		2006-07-11
PCT/US2007/073202 WO2008008805A2 (fr)	2006-07-11	2007-07-11	Toxines clostridiennes modifiées à capacité de translocation améliorée et à activité modifiée de ciblage des cellules qui ne sont pas cibles des toxines clostridiennes

Publications (1)

Publication Number	Publication Date
CA2657521A1 true CA2657521A1 (fr)	2008-01-17

Family

ID=38924120

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002657521A Abandoned CA2657521A1 (fr)	2006-07-11	2007-07-11	Toxines clostridiennes modifiees a capacite de translocation amelioree et a activite modifiee de ciblage des cellules qui ne sont pas cibles des toxines clostridiennes

Country Status (5)

Country	Link
EP (1)	EP2038299A2 (fr)
JP (1)	JP2009543558A (fr)
AU (1)	AU2007272517B2 (fr)
CA (1)	CA2657521A1 (fr)
WO (1)	WO2008008805A2 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9617671D0 (en) *	1996-08-23	1996-10-02	Microbiological Res Authority	Recombinant toxin fragments
US7192596B2 (en)	1996-08-23	2007-03-20	The Health Protection Agency Ipsen Limited	Recombinant toxin fragments
CA2658260A1 (fr) *	2006-07-11	2008-01-17	Allergan, Inc.	Toxines clostridiennes modifiees a capacite de translocation amelioree et a activite modifiee de ciblage des cellules cibles des toxines clostridiennes
EP2719392B1 (fr)	2008-06-12	2019-07-24	Ipsen Bioinnovation Limited	Protéines de fusion pour leur utilisation dans le traitement de l'acromégalie
CN107446053A (zh)	2008-06-12	2017-12-08	益普生生物创新有限公司	癌症的抑制
GB0820970D0 (en)	2008-11-17	2008-12-24	Syntaxin Ltd	Suppression of cancer
RU2543650C2 (ru)	2009-03-13	2015-03-10	Аллерган, Инк.	Иммунологические тесты на активность эндопептидаз с измененной нацеленностью
US20100303788A1 (en) *	2009-05-29	2010-12-02	Allergan, Inc.	Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases
US20100303756A1 (en) *	2009-05-29	2010-12-02	Allergan, Inc.	Methods of Treating Urogenital-Neurological Disorders Using Interleukin Retargeted Endopepidases
US20100303794A1 (en) *	2009-05-29	2010-12-02	Allergan, Inc.	Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases
US20100303791A1 (en) *	2009-05-29	2010-12-02	Allergan, Inc.	Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases
US20100303798A1 (en) *	2009-05-29	2010-12-02	Allergan, Inc.	Methods of Treating Urogenital-Neurological Disorders Using Neurotrophin Retargeted Endopepidases
US8198229B2 (en) *	2009-05-29	2012-06-12	Allergan, Inc.	Methods of treating urogenital-neurological disorders using galanin retargeted endopepidases
US20100303757A1 (en) *	2009-05-29	2010-12-02	Allergan, Inc.	Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases
US20100303789A1 (en) *	2009-05-29	2010-12-02	Allergan, Inc.	Methods of Treating Chronic Neurogenic Inflammation Using Neurotrophin Retargeted Endopepidases
US20100303783A1 (en) *	2009-05-29	2010-12-02	Allergan, Inc.	Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases
RU2569185C2 (ru)	2010-01-25	2015-11-20	Аллерган, Инк.	Способы внутриклеточного превращения одноцепочечных белков в их двухцепочечную форму
UA108646C2 (xx)	2010-05-20	2015-05-25		Клостридіальні токсини, що руйнуються
WO2012051447A1 (fr)	2010-10-14	2012-04-19	Allergan, Inc.	Administration ciblée de modulateurs d'exocytose ciblés au ganglion sphénopalatin pour traiter les troubles liés aux céphalées
US20120244188A1 (en)	2011-03-25	2012-09-27	Allergan, Inc.	Treatment of Sensory Disturbance Disorders
US20120251574A1 (en)	2011-03-28	2012-10-04	Allergan, Inc.	Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions
US20120251573A1 (en)	2011-03-28	2012-10-04	Allergan, Inc.	Endopeptidase Treatment of Neuroendocrine Disorders
US20120251575A1 (en)	2011-03-28	2012-10-04	Allergan, Inc.	Endopeptidase Treatment of Involuntary Movement Disorders
WO2012135304A1 (fr)	2011-03-29	2012-10-04	Allergan, Inc.	Troubles du nerf vague
US20120251515A1 (en)	2011-03-29	2012-10-04	Allergan, Inc.	Endopeptidase Treatment of Cosmesis Disorders
US20120251519A1 (en)	2011-03-29	2012-10-04	Allergan, Inc.	Endopeptidase Treatment of Smooth Muscle Disorders
US20120251518A1 (en)	2011-03-29	2012-10-04	Allergan, Inc.	Endopeptidase Treatment of Sexual Dysfunction Disorders
GB201108108D0 (en)	2011-05-16	2011-06-29	Syntaxin Ltd	Therapeutic fusion proteins
WO2012174123A1 (fr)	2011-06-13	2012-12-20	Allergan, Inc.	Traitement de traumatismes psychologiques
US20130171122A1 (en)	2011-12-29	2013-07-04	Allergan, Inc.	Endopeptidase and neurotoxin combination treatment of bladder disorders
US20140056870A1 (en) *	2012-08-27	2014-02-27	Allergan, Inc.	Fusion proteins
JP2015534814A (ja) *	2012-10-31	2015-12-07	イプセンバイオイノベーションリミテッド	組換えクロストリジウムボツリヌス神経毒
GB201219602D0 (en) *	2012-10-31	2012-12-12	Syntaxin Ltd	Recombinant clostridium botulinum neurotoxins
WO2014100019A1 (fr)	2012-12-18	2014-06-26	Allergan, Inc.	Traitement prophylactique de la récurrence de l'herpès
DK3242884T3 (da)	2015-01-09	2021-04-19	Ipsen Bioinnovation Ltd	Kationiske neurotoksiner
BR112018003782A2 (pt)	2015-08-27	2018-09-25	Ipsen Pharma Sas	composições e métodos para o tratamento da dor
JP7229247B2 (ja)	2018-01-29	2023-02-27	イプセンバイオファームリミテッド	非ニューロンｓｎａｒｅ切断性ボツリヌス神経毒
CN112165955A (zh)	2018-05-21	2021-01-01	益普生生物制药有限公司	抑制骨癌引起的异常性疼痛
GB201815817D0 (en)	2018-09-28	2018-11-14	Ispen Biopharm Ltd	Clostridial neurotoxins comprising and exogenous activation loop
US20220016221A1 (en)	2018-12-05	2022-01-20	Ipsen Biopharm Limited	Treatment of symptoms of traumatic brain injury
GB201900621D0 (en)	2019-01-16	2019-03-06	Ipsen Biopharm Ltd	Labelled polypeptides
GB201914034D0 (en)	2019-09-30	2019-11-13	Ipsen Biopharm Ltd	Treatment of neurological disorders
GB202100566D0 (en)	2021-01-15	2021-03-03	Ipsen Biopharm Ltd	Treatment of brain damage
GB202104294D0 (en)	2021-03-26	2021-05-12	Ipsen Biopharm Ltd	Clostridial neurotoxins comprising an exogenous activation loop
KR20230155007A (ko)	2021-03-30	2023-11-09	입센 바이오팜 리미티드	통증 ＆ 염증성 장애의 치료를 위한 촉매 불활성 클로스트리디움 신경독소
WO2022208091A1 (fr)	2021-03-30	2022-10-06	Ipsen Biopharm Limited	Traitement de troubles inflammatoires et de la douleur
GB202116795D0 (en)	2021-11-22	2022-01-05	Ipsen Biopharm Ltd	Treatment of visceral pain
GB202214232D0 (en)	2022-09-28	2022-11-09	Ispen Biopharm Ltd	Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en)	2022-09-28	2022-11-09	Ipsen Biopharm Ltd	Clostridial neurotoxins comprising an activating endosomal protease cleavage site
AU2023351434A1 (en)	2022-09-30	2025-03-06	Ipsen Biopharm Limited	Clostridial neurotoxin for use in a treatment of bladder pain syndrome
GB202318884D0 (en)	2023-12-11	2024-01-24	Ipsen Biopharm Ltd	Formulation
GB202320108D0 (en)	2023-12-28	2024-02-14	Ipsen Biopharm Ltd	Biosensor
GB202404021D0 (en)	2024-03-20	2024-05-01	Ipsen Biopharm Ltd	Cell-based neurotoxin assay

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5135736A (en)	1988-08-15	1992-08-04	Neorx Corporation	Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US7192596B2 (en)	1996-08-23	2007-03-20	The Health Protection Agency Ipsen Limited	Recombinant toxin fragments
GB9617671D0 (en)	1996-08-23	1996-10-02	Microbiological Res Authority	Recombinant toxin fragments
AU777556B2 (en)	1999-08-25	2004-10-21	Allergan, Inc.	Activatable recombinant neurotoxins
US20060024331A1 (en) *	2004-08-02	2006-02-02	Ester Fernandez-Salas	Toxin compounds with enhanced membrane translocation characteristics
EP1982997B1 (fr) *	2004-09-01	2012-08-08	Allergan, Inc.	Toxines clostridiennes dégradables
DE102004043009A1 (de) *	2004-09-06	2006-03-23	Toxogen Gmbh	Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
JP2008535486A (ja)	2005-03-15	2008-09-04	アラーガン、インコーポレイテッド	クロストリジウム毒素標的細胞に対する改変された標的能力を有する修飾クロストリジウム毒素
CA2658260A1 (fr) *	2006-07-11	2008-01-17	Allergan, Inc.	Toxines clostridiennes modifiees a capacite de translocation amelioree et a activite modifiee de ciblage des cellules cibles des toxines clostridiennes

2007
- 2007-07-11 CA CA002657521A patent/CA2657521A1/fr not_active Abandoned
- 2007-07-11 WO PCT/US2007/073202 patent/WO2008008805A2/fr not_active Ceased
- 2007-07-11 JP JP2009519645A patent/JP2009543558A/ja active Pending
- 2007-07-11 EP EP07812774A patent/EP2038299A2/fr not_active Withdrawn
- 2007-07-11 AU AU2007272517A patent/AU2007272517B2/en not_active Ceased

Also Published As

Publication number	Publication date
WO2008008805A3 (fr)	2008-04-10
AU2007272517B2 (en)	2013-09-26
EP2038299A2 (fr)	2009-03-25
AU2007272517A1 (en)	2008-01-17
JP2009543558A (ja)	2009-12-10
WO2008008805A2 (fr)	2008-01-17

Publication	Publication Date	Title
AU2007272517B2 (en)	2013-09-26	Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
AU2007272515B2 (en)	2013-09-26	Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
US8518417B1 (en)	2013-08-27	Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
US8052979B2 (en)	2011-11-08	Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
US7892565B2 (en)	2011-02-22	Degradable clostridial toxins
US8021859B2 (en)	2011-09-20	Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
US20140127784A1 (en)	2014-05-08	Modified clostridial toxins comprising an integrated protease cleavage site-binding domain
EP2001902B1 (fr)	2013-03-27	Toxines clostridiales modifiées présentant des capacités de ciblage modifiées destinées à des cellules cibles de toxines clostridiales

Legal Events

Date	Code	Title	Description
2012-04-16	EEER	Examination request
2016-12-12	FZDE	Dead	Effective date: 20161031